Ticker

Revenue increased 22% for the quarter ended December 31, 2025 and 33% for the nine months ended December 31, 2025 compared to prior year Net loss and net loss per share decreased from prior year for both the three months and nine months ended December 31, 2025 EBITDAS loss decreased by $0.4 million and $0.9 million for the three and nine months ended December 31, 2025 compared to prior year BOULDER, COLORADO /…

BOULDER, CO / ACCESS Newswire / January 28, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, and animal health care, today announced the appointment of Vanessa Jacoby, Chief…

Sonoma Pharmaceuticals (NASDAQ: SNOA - Get Free Report) and Ocular Therapeutix (NASDAQ: OCUL - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, earnings and profitability. Profitability This table compares Sonoma Pharmaceuticals and Ocular

Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $3.71 and traded as high as $3.89. Sonoma Pharmaceuticals shares last traded at $3.62, with a volume of 67,888 shares traded. Wall